Compass Pathways Plc ADR(CMPS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.62 | Insider Own | 1.61% | Shs Outstand | 138.5M | Perf Week | -0.76% |
| Market Cap | 1.64B | Forward P/E | - | EPS next Y | 26.18% | Insider Trans | - | Shs Float | 136.2M | Perf Month | -10.73% |
| Enterprise Value | 1.26B | PEG | - | EPS next Q | -0.36 | Inst Own | 64.75% | Short Float | 12.97% | Perf Quarter | 8.35% |
| Income | -0.41B | P/S | - | EPS this Y | 26.83% | Inst Trans | -2.51% | Short Ratio | 6.56 | Perf Half Y | 39.93% |
| Sales | 0.00B | P/B | 18.96 | EPS next 5Y | 27.55% | ROA | -102.08% | Short Interest | 17.67M | Perf YTD | 71.16% |
| Book/sh | 0.62 | P/C | 3.77 | EPS past 3/5Y | -12.71% -12.77% | ROE | -329.72% | 52W High | -25.58% ($15.87) | Perf Year | 80.58% |
| Cash/sh | 3.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -296.74% | 52W Low | 142.01% ($4.88) | Perf 3Y | 123.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -99.37% | Gross Margin | - | Volatility(W/M) | 4.73% 5.18% | Perf 5Y | -70.12% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | -352.05% | Profit Margin | - | RSI (14) | 47.84 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.3 | Sales Q/Q | - | SMA20 | 2.06% ($11.57) | Beta | 2.44 | Target Price | $23.35 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/11/3 | SMA50 | -9.31% ($13.02) | Rel Volume | 0.84 | Prev Close | $11.05 |
| Employees | 156 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | -384.41% - | SMA200 | 14.33% ($10.33) | Avg Volume(3M) | 2.69M | Price | $11.81 |
| IPO | 2020/9/18 | Option/Short | Yes/Yes | Trades | 9946 | Volume | 2,275,308 | Change | 6.88% |
A clinical-stage biotech company developing therapeutics for mental health disorders. It develops drug candidates using a differentiated therapeutic approach targeting mental health conditions such as treatment-resistant depression, and holds a lead candidate in late-stage clinical trials. Positioned as a growth-stage biotech targeting the underserved area of mental health, this stock is driven by business progress and market sentiment.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
Next earnings report: November 3
6 days to go.
CMPS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +26.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -70.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 64.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #25 of 48 in the industry
Based on market cap of $2B.
ARDT#23 Ardent Health Inc $2B PER 21.5 
HCSG#24 Healthcare Services Group Inc $2B PER 16.4 CMPS#25 Compass Pathways Plc ADR $2B PER - 
SNDA#26 Sonida Senior Living Inc $2B PER - 
AGL#27 Agilon Health Inc $2B PER - 
FAQ
What kind of company is CMPS?
CMPS belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of CMPS?
The market cap of CMPS is approximately $1.6B, ranking 2,234 within its sector.
What is the 52-week high and low for CMPS?
CMPS has recorded a 52-week high of $15.87 and a low of $4.88.
